Badreddin Edris - 21 Jan 2026 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Director
Signature
/s/John R. Moore Attorney-in-Fact for Badreddin Edris
Issuer symbol
EWTX
Transactions as of
21 Jan 2026
Net transactions value
-$3,229,202
Form type
4
Filing time
23 Jan 2026, 13:34:18 UTC
Previous filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Edris Badreddin Director C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER /s/John R. Moore Attorney-in-Fact for Badreddin Edris 21 Jan 2026 0001786966

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $5,339 +13,690 +69% $0.3900 33,510 21 Jan 2026 Direct
transaction EWTX Common Stock Options Exercise $11,031 +17,236 +51% $0.6400 50,746 21 Jan 2026 Direct
transaction EWTX Common Stock Options Exercise $20,194 +10,463 +21% $1.93 61,209 21 Jan 2026 Direct
transaction EWTX Common Stock Options Exercise $128,301 +66,477 +109% $1.93 127,686 21 Jan 2026 Direct
transaction EWTX Common Stock Options Exercise $5,400 +7,605 +6% $0.7100 135,291 21 Jan 2026 Direct
transaction EWTX Common Stock Sale $403,034 -13,690 -10% $29.44 121,601 21 Jan 2026 Direct F1, F2
transaction EWTX Common Stock Sale $507,428 -17,236 -14% $29.44 104,365 21 Jan 2026 Direct F1, F2
transaction EWTX Common Stock Sale $223,891 -7,605 -7.3% $29.44 96,760 21 Jan 2026 Direct F1, F2
transaction EWTX Common Stock Sale $308,031 -10,463 -11% $29.44 86,297 21 Jan 2026 Direct F1, F2
transaction EWTX Common Stock Sale $1,957,083 -66,477 -77% $29.44 19,820 21 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -10,463 -100% $0.000000 0 21 Jan 2026 Common Stock 10,463 $1.93 Direct
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -66,477 -100% $0.000000 0 21 Jan 2026 Common Stock 66,477 $1.93 Direct
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -7,605 -100% $0.000000 0 21 Jan 2026 Common Stock 7,605 $0.7100 Direct
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -17,236 -100% $0.000000 0 21 Jan 2026 Common Stock 17,236 $0.6400 Direct
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -13,690 -100% $0.000000 0 21 Jan 2026 Common Stock 13,690 $0.3900 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.